EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN TREATMENT OF NON-SMALL CELL LUNG CANCER

KILIÇKAP S.

NOBEL MEDICUS, vol.14, no.3, pp.5-8, 2018 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 14 Issue: 3
  • Publication Date: 2018
  • Journal Name: NOBEL MEDICUS
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus
  • Page Numbers: pp.5-8
  • Hacettepe University Affiliated: Yes

Abstract

Mutation of epidermal growth factor receptor (EGFR) is one of the targeted mutations in treatment of non-small cell lung cancer (NSCLC). Mutation of EGFR occurs in 15-40% of all patients with NSCLC. In this review, efficacy of different EGFR inhibitors used in NSCLC treatment is evaluated.